CCR2 contributes to the recruitment of monocytes and leads to kidney inflammation and fibrosis development

Imagem de Miniatura
Arquivos
art_BRAGA_CCR2_contributes_to_the_recruitment_of_monocytes_and_2018.PDF (3.97 MB)
Citações na Scopus
45
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER BASEL AG
Autores
BRAGA, Tarcio Teodoro
CORREA-COSTA, Matheus
SILVA, Reinaldo Correia
CRUZ, Mario Costa
HIYANE, Meire Ioshie
SILVA, Joao Santana da
PEREZ, Katia Regina
CUCCOVIA, Iolanda Midea
Autor de Grupo de pesquisa
Citação
INFLAMMOPHARMACOLOGY, v.26, n.2, p.403-411, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Chemokines are a large family of proteins that, once associated to its receptor on leukocytes, stimulate their movement and migration from blood to tissues. Once in the tissue, immune cells trigger inflammation that, when uncontrolled, leads to fibrosis development. Among the immune cells, macrophages take a special role in fibrosis formation, since macrophage depletion reflects less collagen deposition. The majority of tissue macrophages is derived from monocytes, especially monocytes expressing the chemokine receptor CCR2. Here, we investigated the role of infiltrating CCR2(+) cells in the development of fibrosis, and specifically, the dynamic of infiltration of these cells into kidneys under chronic obstructive lesion. Using liposome-encapsulated clodronate, we observed that macrophage depletion culminated in less collagen deposition and reduced chemokines milieu that were released in the damaged kidney after obstructive nephropathy. We also obstructed the kidneys of CCL3(-/-), CCR2(-/-), CCR4(-/-), CCR5(-/-), and C57BL/6 mice and we found that among all animals, CCR2(-/-) mice demonstrated the more robust protection, reflected by less inflammatory and Th17-related cytokines and less collagen formation. Next we evaluated the dynamic of CCR2(+/rfp) cell infiltration and we observed that they adhere onto the vessels at early stages of disease, culminating in increased recruitment of CCR2(+/rfp) cells at later stages. On the other hand, CCR2(rfp/rfp) animals exhibited less fibrosis formation and reduced numbers of recruited cells at later stages. We have experimentally demonstrated that inflammatory CCR2(+) cells that reach the injured kidney at initial stages after tissue damage are responsible for the fibrotic pattern observed at later time points in the context of UUO.
Palavras-chave
CCR2(+) monocytes, Fibrosis, UUO
URI
https://observatorio.fm.usp.br/handle/OPI/26567
Referências
  1. Adegunsoye A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00516
  2. BOHLE A, 1992, PATHOL RES PRACT, V188, P908, DOI 10.1016/S0344-0338(11)80252-9
  3. Braga TT, 2016, IMMUN INFLAMM DIS, V4, P300, DOI 10.1002/iid3.114
  4. Braga TT, 2012, MOL MED, V18, P1231, DOI 10.2119/molmed.2012.00131
  5. Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213
  6. Cao Q, 2015, PHYSIOLOGY, V30, P183, DOI 10.1152/physiol.00046.2014
  7. Cassado AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00225
  8. Chousterman BG, 2016, J AM SOC NEPHROL, V27, P792, DOI 10.1681/ASN.2015010009
  9. Dey A, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00683
  10. Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461
  11. Furuichi K, 2003, J AM SOC NEPHROL, V14, P1066, DOI 10.1097/01.ASN.0000059339.14780.E4
  12. Furuichi K, 2003, J AM SOC NEPHROL, V14, P2503, DOI 10.1097/01.ASN.0000089563.63641.A8
  13. Furuichi K, 2009, CLIN EXP NEPHROL, V13, P9, DOI 10.1007/s10157-008-0119-5
  14. Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
  15. Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
  16. Giunti S, 2010, CURR VASC PHARMACOL, V8, P849, DOI 10.2174/157016110793563816
  17. Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
  18. Han H, 2017, J PATHOL, V241, P80, DOI 10.1002/path.4831
  19. Kashyap S., 2016, RENAL PHYSL, V310, pF372
  20. Katagiri D, 2016, KIDNEY INT, V89, P374, DOI 10.1038/ki.2015.327
  21. Kawamura E, 2015, MOD RHEUMATOL, V25, P571, DOI 10.3109/14397595.2014.1001474
  22. Kim SM, 2015, TRANSL RES, V166, P375, DOI 10.1016/j.trsl.2015.04.013
  23. Kitagawa K, 2004, AM J PATHOL, V165, P237, DOI 10.1016/S0002-9440(10)63292-0
  24. Kitamoto K, 2009, J PHARMACOL SCI, V111, P285, DOI 10.1254/jphs.09227FP
  25. Kufareva I, 2015, IMMUNOL CELL BIOL, V93, P372, DOI 10.1038/icb.2015.15
  26. Lefebvre E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158156
  27. Mehrotra P, 2016, AM J PHYSIOL-RENAL, V00462
  28. Mehrotra P, 2015, KIDNEY INT, V88, P776, DOI 10.1038/ki.2015.200
  29. Menezes GB, 2008, EUR J PHARMACOL, V598, P118, DOI 10.1016/j.ejphar.2008.08.037
  30. Mia S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135235
  31. Nakashima H, 2004, LUPUS, V13, P165, DOI 10.1191/0961203304lu523oa
  32. O'Connor T, 2015, ENDOCR METAB IMMUNE, V15, P105, DOI 10.2174/1871530315666150316120920
  33. Peng XG, 2015, J IMMUNOL, V195, P2797, DOI 10.4049/jimmunol.1403209
  34. Porubsky S, 2004, AM J PATHOL, V164, P2175, DOI 10.1016/S0002-9440(10)63775-3
  35. Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
  36. Sallusto F, 2008, NAT IMMUNOL, V9, P949, DOI 10.1038/ni.f.214
  37. Sean Eardley K, 2005, KIDNEY INT, V68, P437, DOI 10.1111/j.1523-1755.2005.00422.x
  38. Segerer S, 2000, J AM SOC NEPHROL, V11, P152
  39. Segerer S, 2005, THESCIENTIFICWORLDJO, V5, P835, DOI 10.1100/tsw.2005.105
  40. Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309
  41. Sezgin I, 2011, INTERNAL MED, V50, P2457, DOI 10.2169/internalmedicine.50.5119
  42. Shen B, 2016, STEM CELLS INT, DOI 10.1155/2016/1240301
  43. Silva Reinaldo Correia, 2016, Pathophysiology, V23, P229, DOI 10.1016/j.pathophys.2016.07.002
  44. Sipos A, 2007, KIDNEY INT, V72, P1188, DOI 10.1038/sj.ki.5002461
  45. Stroo I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123203
  46. Sung SA, 2007, NEPHRON EXP NEPHROL, V105, pE1, DOI 10.1159/000096859
  47. Trujillo G, 2008, AM J PATHOL, V172, P1209, DOI 10.2353/ajpath.2008.070832
  48. Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
  49. Vanhove T., 2016, TRANSPLANTATION
  50. Vielhauer V, 2004, KIDNEY INT, V66, P2264, DOI 10.1111/j.1523-1755.2004.66038.x
  51. Weir MR, 2015, LANCET DIABETES ENDO, V3, P666, DOI 10.1016/S2213-8587(15)00286-7
  52. Wick G, 2013, ANNU REV IMMUNOL, V31, P107, DOI 10.1146/annurev-immunol-032712-095937
  53. Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
  54. Xia YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077493
  55. Yang J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149926
  56. Yuan A, 2015, AM J PHYSIOL-RENAL, V308, pF459, DOI 10.1152/ajprenal.00146.2014

Coleções
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - ODS/03